trending Market Intelligence /marketintelligence/en/news-insights/trending/aVSkFcxV1zKrwpqh4KTBiw2 content esgSubNav
In This List

Lilly's Verzenio fails phase 3 trial in non-small cell lung cancer

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Lilly's Verzenio fails phase 3 trial in non-small cell lung cancer

Eli Lilly and Co. said the phase 3 trial of Verzenio as a monotherapy in KRAS-mutated, advanced non-small lung cancer failed to meet its main goal.

Results from the JUNIPER study showed that Verzenio was not superior to Roche Holding AG and Astellas Pharma Inc.'s Tarceva, or erlotinib, and did not meet the end goal for overall survival.

However, an analysis of the secondary study endpoints of both progression-free survival and overall response rate showed evidence of monotherapy activity in the Verzenio arm of the study.

The U.S. Food and Drug Administration approved Verzenio, or abemaciclib, in September to treat advanced or metastatic breast cancer that has progressed following endocrine therapy.